

Taiwan Perspectives from the **ONWARD** Initiative: Advancing Equitable Access and System Readiness in Cancer Care

ONWARD: Oncology Needs, Workforce, Access,
Research & Disparities

Authors:

Laurence I, Slapikaite E, Nicod, E, Whittal A

Funding and Contributions

This paper was funded by AbbVie. The structure and content were developed collaboratively by the authors listed above.

Introduction	3
Healthcare system-related barriers	5
Reimbursement-related barriers	6
Exploring how to address key barriers: Illustrative approaches	8
Call to action: Coordinated stakeholder action grounded in recognition of unmet need in oncology	9
Bibliography	10

Introduction

Cancer represents a significant and growing global burden, making it a key political priority and underscoring the need for continued innovation and improved access to care

Globally, cancer remains the second leading cause of death, accounting for ~10 million deaths annually¹. Rising incidence driven by aging populations², as well as higher rates among younger people³, is placing a growing burden on patients, caregivers, healthcare systems and society⁴.

This context has contributed to cancer becoming firmly established as a global policy priority, reflected in major international and national initiatives⁵⁻⁷.

Cancer has been the leading cause of death in Taiwan for 44 consecutive years and was responsible for ~55,000 deaths in 202^{8,9}. The government, under President Lai Ching-te, has made a strong commitment to combating cancer with the primary goal of reducing age-standardized cancer mortality rate by at least one-third by 2030⁸.

Figure 1. Global cancer burden in numbers



Despite meaningful advancements in cancer care, substantial unmet patient needs persist, driven by the complexity of the disease and the diversity of affected populations

Diagnosis and treatment outcomes have steadily improved in many cancer types, reflecting advances in screening (e.g., breast and lung) and new treatments (e.g., some myelomas)^{10,11}.

At the same time, cancer is highly heterogeneous and adaptive, requiring personalized, multi-line treatment strategies rather than a one-size-fits-all approach^{12,13}. This complexity has contributed to an increasingly crowded oncology landscape, which can create a perception that patient needs are largely met, and new therapies offer limited incremental value. However, this overlooks critical gaps in certain diagnostic and treatment settings where current options offer suboptimal response rates, tolerability, and/or quality of life (QoL). See Figure 2 for examples.

Figure 2. Oncology indications with important outstanding unmet needs¹⁴⁻²⁹

Platinum-resistant ovarian cancer (PROC)	Associated with poor prognosis: <1-year median overall survival in many cohorts, limited treatment options, and declining QoL due to high symptom burden and side effects of existing treatments ¹²⁻¹⁴
Metastatic colorectal cancer (mCRC)	Only ~50% of frontline patients achieve any response to current therapies, with efficacy declining sharply with each line of therapy ¹⁵⁻¹⁸
Chronic lymphocytic leukemia (CLL)	Continuous, indefinite treatment with current regimens is associated with cumulative toxicities, and a considerable QoL and health-economic burden ¹⁹
Late line multiple myeloma (MM)	Novel therapies offer improved efficacy but with important trade-offs related to safety and treatment burden • CAR T: immune-mediated toxicities²⁰, administration limited to specialist centers²¹, and long wait times for treatment (~10-15% MM patients die between waitlist and CAR T infusion²²⁻²⁴) • Bispecifics: infection risk²⁵ and burdensome dosing regimens (step up, treat to progression)^{26,27}


Access to innovation is essential to address persistent unmet needs, yet it remains constrained by systemic healthcare and reimbursement barriers and by an increasingly challenging global environment

Addressing access barriers is critical to ensuring that innovation translates into meaningful patient and societal benefit. This paper explores six key barriers to the timely uptake of innovation, which can make a significant difference for patients globally, from initial diagnosis to novel emerging treatments (see Figure 3). The intention of this paper is to highlight global access challenges and illustrate these with relevant country-level examples.

Importantly, these barriers exist in a rapidly changing global environment, marked by concern over the sustainability of increasing cancer costs⁴, competing demands on public budgets³⁰, and shifting US pharmaceutical policy that risks launch delays and reprioritization in other markets³¹. Evolving implications of the Most Favored Nation (MFN) policy has the potential to apply additional pressure on existing barriers, especially in systems with relatively lower drug prices (e.g. Japan, South Korea, Australia³²) and including those with historically strong access to innovation (e.g., Japan³³).

The effects are cumulative: in Japan for instance, 70% of new medicines in late-stage clinical development in the United States (US) and European Union (EU) have not begun development there³⁴, reflecting the unpredictable drug pricing environment and potential shortcomings in the policy ecosystem in terms of incentivizing innovation. This context presents a critical opportunity for countries to strengthen their health systems and adapt policies to support better cancer care in the future.

Figure 3. System-level healthcare and reimbursement barriers limiting access to oncology innovation



Healthcare system-related barriers

1. Limitations in diagnostic provision and referral pathways

Diagnosis and referral to an appropriate specialist are critical pre-requisites for ensuring timely patient access to innovative oncology treatments. Recent advances in colorectal cancer (CRC) screenings, for example, are associated with earlier intervention and a reduction in morbidity and mortality globally³⁵.

While cancer screening has improved significantly in high-income settings, long wait times for specialists and referral bottlenecks remain commonplace³⁶. Two-thirds of OECD countries report waiting times for cancer care (including diagnosis) as an issue, and over half have developed waiting time strategies, sometimes as part of national cancer control plans³⁶. In China, despite significant progress with respect to cancer screening programs and guidelines, challenges remain³⁷ and diagnostic delays persist^{38–40}. Study findings evaluating Europe's Beating Cancer Plan found that, despite progress in advancing cancer control at EU and national levels, gaps remain in implementation, screening, monitoring, and equitable access to molecular diagnostics and personalized cancer medicine⁴¹.

Sub-national disparities in access to screening and diagnosis are a significant challenge. Twice as many people participate in CRC screening in northern Italian regions versus southern regions, attributed to better access and public awareness in the north^{42,43}. In Australia and Canada, specialist services (e.g., imaging) are concentrated in urban areas resulting in rural access gaps that are frequently exacerbated by other socio-economic inequalities^{44,45}.

Beyond screening, access to biomarker testing required for precision oncology medicines is inadequate in most countries due to lack of reimbursement and limited capacity for testing and processing^{46,47}. This is a challenge in many high unmet need indications, which require biomarker testing to guide personalized treatment approaches (e.g., supporting testing for FRA-targeted therapy in ovarian cancer and comprehensive molecular profiling to identify CRC patients eligible for targeted therapies or immunotherapies)^{48,49}.

2. Specialist healthcare workforce shortages

Cancer care is highly specialized and depends on a skilled workforce, such that shortages in appropriately trained staff can be a limiting factor for patient access. Meanwhile, oncology workforce shortages are a nearly universal healthcare system challenge due to rising cancer burden, a limited training pipeline, and reliance on a large number of different specialists for effective treatment^{50,51}.

For instance, China's rising cancer burden places increased demands on an already resource-constrained healthcare system, where limited availability of trained oncology clinical professionals can hinder capacity and access to care^{52,53}.

In Canada and Australia, regional variability in oncology workforce and specialist capacity are a focus area for policy^{54,55}. In both countries this challenge is characterized by recruitment and retention issues, a demanding work environment contributing to provider burnout, and education and training systems that fail to keep pace with workforce needs^{54–56}. Finally, lower availability of specialist oncology workforce in remote and rural areas has significant consequences, as seen in Australia, where it can contribute to poorer survival outcomes⁵⁷.

Looking ahead, AI-enabled administrative workflows could help health systems use scarce specialist capacity more efficiently by automating document review, triage, and prior-authorization support.

Taiwan's NHIA provides an emerging example, with digital and AI-assisted review tools intended to reduce manual review burden, improve consistency, and accelerate patient access to innovative cancer treatments⁵⁸.

3. Insufficient data infrastructure

Data infrastructure is a core health system capability that enables effective patient identification, timely diagnosis, and longitudinal outcomes tracking to support reimbursement and access. It is crucial in cancer care due to the need for highly coordinated care delivery, and particularly for advanced therapies (e.g., CAR T) where long-term evidence generation may be needed to support clinical and reimbursement decision making^{59,60}.

However, establishing and maintaining effective national data infrastructure requires significant investment and interoperability across sub-national jurisdictions. In decentralized systems this can be very challenging, since local control over data systems often results in data silos, fragmentation and limited interoperability (e.g., between Canadian provinces, Italian regions, and Australian states)^{61–63}.

Collection of real-world data (RWD) with the support of registries can provide important insights into treatment effectiveness, safety and patient outcomes in routine clinical practice. This is particularly valuable in oncology where populations are often more heterogeneous than those included in controlled trials⁶⁴. However, RWD is not routinely collected, and the resulting data can vary substantially in quality, completeness, and interoperability, particularly compared to data collected in controlled trial environments. This can hinder its perceived validity and credibility for use to support risk-sharing access solutions (e.g., managed-entry agreements)⁶⁵.

Reimbursement-related barriers

4. Practical challenges to assessing magnitude of clinical benefit

Value offered by novel therapies, particularly the magnitude of clinical benefit, is important for both ensuring payer value-for-money and rewarding innovation. In oncology, however, distinct evidence challenges and high unmet need make assessments using conventional evidence standards and value frameworks difficult.

Acceptance of alternative (i.e., non-overall survival) endpoints and trial designs varies across countries, but these are often associated with lower value rating compared with 'typical' evidence packages^{66,67}. Although they can complicate interpretation of comparative outcomes, oncology often necessitates single-arm trials, cross-over designs, and surrogate endpoints (e.g. minimal residual disease in MM⁶⁸) to meet ethical imperatives and accelerate evidence generation in fast-progressing, high-unmet-need indications^{69–71}. Differing standards of care across countries further complicates development of evidence packages that reflect all relevant context (e.g., a recent cohort study in CLL found substantial differences between the US and China in terms of therapy patterns and specifically the frequency of BTK inhibitors and agents used in first line⁷²).

Furthermore, patient perspectives on what constitutes a meaningful survival or QoL benefit are crucial in oncology, particularly where prognosis is very poor⁷³. One example of this is PROC where symptoms control and maintaining QoL are key therapy goals⁷⁴. Another is enabling treatment-free periods in CLL (versus intensive, indefinite program of infusions), helping patients to reengage in social and economic activities and have a more positive outlook on life^{75,76}. Despite this, consideration of patient-reported outcomes and preferences in health technology assessment remains inconsistent and sub-optimal in many systems, often due to validity concerns and issues integrating these data alongside clinical and economic evidence.

5. Healthcare system affordability and budget constraints

While healthcare system budget constraints are inevitable and fiscal responsibility is critical, challenges arise when pricing and reimbursement policies prioritize short-term cost containment over value recognition and access to innovative oncology treatments. This tension is evident across markets (including China⁷⁷, Australia⁷⁸, Canada⁷⁹, and in Europe^{80–82}). It is often associated with lengthy delays between regulatory approval and reimbursement, as well as differences in access between countries (e.g., between 2021 and 2024, the median time to availability of oncology products was 420 days in Italy, 761 days in France⁸³).

Disproportionate focus on cost-containment may also lead payers to benchmark novel therapies against low-cost supportive care or generics. This approach is unlikely to adequately reflect the significant investment in research and development and additional therapeutic value of new treatments, potentially weakening incentives for continued innovation in oncology⁸⁴.

Furthermore, annual healthcare budgets and standard economic evaluation frameworks may not reflect downstream savings realized beyond the first year (e.g., reductions in time on treatment after one year, treatments with one-time administration)⁸⁵. Accordingly, reimbursement decision-making should consider the broader long-term clinical and economic value of treatment (including delayed disease progression, QoL improvement, reduction in mortality and downstream complications) as well as potential healthcare cost savings over time.

In Taiwan, progress has been made toward balancing cost containment with improved access to innovative oncology treatments in lung, breast and colorectal cancers by aligning reimbursement criteria with NCCN guidelines⁸⁶. Ideally, this trend continues in cases where reimbursement criteria remain more restrictive than guideline-recommended care.

6. Difficulties managing increasingly complex therapies

Oncology is the focus of many innovative treatments which offer significant value, but also inherent additional complexities with value recognition and reimbursement. CAR T, for instance, is an advanced therapy involving single or short-course administration that can deliver long-term and potentially curative benefit, but is also associated with complex manufacturing, high upfront cost and inherent uncertainty about long-term durability^{87,88}. Certain contracting agreements can help manage clinical uncertainty and mitigate budget impact (e.g., outcomes-based agreements, coverage with evidence development). However, these are complex and resource-intensive, relying on robust data collection and financing infrastructures and hence may not be scalable or applicable in all contexts⁸⁹.

Combination regimens are a cornerstone in oncology treatment for their ability to target multiple pathways, improve response rates and delay resistance⁵². Yet, they present unique access challenges across global markets^{90,91}. In Europe, for instance, combinations have lower rate of availability compared to other oncology products (12% lower in Spain and 18% in Italy) and longer time to availability (average +147 days in Spain, +178 days in Italy)⁹².

An issue facing combination therapies is that standard value assessment approaches are not designed to isolate the incremental contribution of each component where clinical outcomes reflect their combined effect⁹³. Another issue is demonstrating cost-effectiveness (CE) because even if the additional component is priced at zero, the first may already be reimbursed at the willingness to pay threshold^{94,95} (important for CE-focused markets, such as Canada⁹⁶). Finally, contracting agreements are often complicated when components are owned by different manufacturers⁹⁰, particularly where this goes against local trade rules and there is a lack of institutional frameworks to support cross-company coordination for this purpose (e.g., in South Korea⁹⁷).

Exploring how to address key barriers: Illustrative approaches

Efforts have been made to address these barriers, offering inspiration for potential ways forward. Figure 4 outlines some examples of directional solutions to these issues across different markets.

Figure 4. System-level healthcare and reimbursement oncology access barriers and potential solutions^{55,98 - 107}



Call to action: Coordinated stakeholder action grounded in recognition of unmet need in oncology

Timely access to novel oncology treatments relies on system readiness as much as scientific progress. Access barriers in oncology today are interconnected, systemic, and shaped by a complex global environment where policy pressures risk exacerbating these barriers and amplify the urgency for solutions.

This is not a call to reinvent healthcare and reimbursement systems, but rather to foster coordinated discussion and alignment across stakeholders on how to optimize current systems and frameworks to improve access to novel oncology therapies. Most importantly, it requires shared recognition of the persistent unmet needs in oncology and the urgency of advancing innovation and access for the benefit of patients, families, and society. There is a real opportunity to close access gaps and ensure that continued progress translates into meaningful benefits for patients, families, and society.

Bibliography

1. WHO. WHO Cancer. <https://www.who.int/news-room/fact-sheets/detail/cancer> (2026).
2. Ju, W. et al. Occurrence of cancer in ageing populations at global and regional levels, 1990 to 2019. *Age Ageing* **52**, (2023).
3. Zhao, J. et al. Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019. *BMJ Oncol.* **2**, (2023).
4. OECD. Tackling the Impact of Cancer on Health, the Economy and Society. *OECD Health Policy Stud.* <https://doi.org/10.1787/85e7c3ba-en> (2024) doi:10.1787/85e7c3ba-en.
5. WHO. WHO Collaborating Centre for global cancer control ushers in a new chapter. <https://www.who.int/news/item/24-06-2024-who-collaborating-centre-for-global-cancer-control-ushers-in-a-new-chapter> (2024).
6. EC. Communication: Europe's Beating Cancer Plan - Public Health. (2021).
7. NIH. Global Review of National Cancer Control Plans - NCI. <https://www.cancer.gov/about-nci/organization/cgh/news-announcements/2024/nccp-global-review-2024> (2024).
8. Presidential Office Press Release. In his recorded address for World Cancer Day, the President emphasized that the government's cancer prevention and control program makes health a vital force for Taiwan's progress. President.gov.tw (2026).
9. Staff writer, with CNA. Lung, pancreatic, ovarian cancer death toll rises. Taipei Times (2026).
10. Goddart, K., Feuer, E. & Mandelblatt, J. Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. *JAMA Oncol. JAMA Netw.* <https://jamanetwork.com/journals/jamaoncology/fullarticle/2827241> (2025).
11. Mettias, S., ElSayed, A., Moore, J. & Berenson, J. R. Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options. *Target. Oncol.* **20**, 247–267 (2025).
12. World Cancer Research. Why Is Cancer So Hard To Cure? (2025).
13. Lovly, C. M., Salama, A. K. S. & Salgia, R. Tumor Heterogeneity and Therapeutic Resistance. *Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet.* **35**, e585–e593 (2016).
14. EMA. Talvey-epar-product-information_en. (2022).
15. EMA. Elrexio-epar-product-information_en. (2024).
16. Kinney, R. E., Nair, S., Kim, C. H., Thomas, M. B. & DelaTorre, M. Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer. *The Oncologist* **28**, e478–e486 (2023).
17. Richardson, D. L., Eskander, R. N. & O'Malley, D. M. Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review. *JAMA Oncol.* **9**, 851–859 (2023).
18. Chen, Z., Macmillan, T. & Herzog, T. Systematic Literature Reviews (SLRs) Of Clinical Outcomes And Patient-Reported Outcomes Of Recommended Treatments For Patients With Platinum-Resistant Ovarian Cancer (PROC). *Value Health* **28**, S27 (2025).
19. Tournigand, C., Andre, T., Achille, E., Lledo, G. & Flesh, M. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. (2004).
20. Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **25**, 1539–1544 (2007).
21. Prager, G. W. et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. *N. Engl. J. Med.* **388**, 1657–1667 (2023).
22. Marjanovic, M., Biljana, K., Bjelobrk Kolarov, I. & Petrovic, N. Third and Later Line Therapy in Metastatic Colorectal Cancer - Current Landscape and Future Perspectives. *J. Med. Radiat. Oncol.* **5**, 16–22 (2025).

23. Waweru, C., Kaur, S., Sharma, S. & Mishra, N. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. *Curr. Med. Res. Opin.* **36**, 1481–1495 (2020).
24. An, J. et al. Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies. *Cancer Med.* **13**, e7372 (2024).
25. Al Hadidi, S., Heslop, H. E., Brenner, M. K. & Suzuki, M. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies. *Mol. Ther.* **32**, 2444–2460 (2024).
26. Portuguese, A. et al. Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center. *Blood* **144**, (2024).
27. Rendo, M. J., Joseph, J. J., Phan, L. M. & DeStefano, C. B. CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges. *Blood Lymphat. Cancer Targets Ther.* **12**, 119–136 (2022).
28. Mateos, M.-V. et al. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. *Haematologica* **108**, 2192–2204 (2023).
29. Bakogeorgou, S. et al. Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials. *Cancers* **17**, 2727 (2025).
30. James, C., Colombo, F., Morgan, D. & Vammalle, C. Finance and health dialogue needed to build resilient health systems. *Bull. World Health Organ.* **102**, 368–369 (2024).
31. Meszarosova, D., Andrews, R. & Mavinkurve, A. Leveling the Field: How the MFN Could Transform Drug Pricing. *Value Health* **28**, (2025).
32. Hemmerman, A., Papamoniadis, V. & Lipschitz, Y. HPR240 Who Pays the Price? International Impacts of US Drug-Cost Benchmarking. *Value Health* **28**, S369 (2025).
33. Hori, K. MFN Drug Pricing Already Affecting 4 Firms' R&D Plans in Japan, EFPIA Chief Flags Fallout. *PHARMA JAPAN* (2025).
34. PhRMA. Securing Japans Future as a Leader in Biopharmaceutical Innovation. (2025).
35. Han, C., Wu, F. & Xu, J. Effectiveness of sigmoidoscopy or colonoscopy screening on colorectal cancer incidence and mortality: a systematic review and meta-analysis of randomized controlled trial. *Front. Oncol.* **14**, 1364923 (2024).
36. OECD. Waiting times: Health at a Glance 2025. (2025).
37. Xia, C. et al. Cancer screening in China: a steep road from evidence to implementation. *Lancet Public Health* **8**, e996–e1005 (2023).
38. Yue, L. et al. Delays in follow-up among women with abnormal results: a retrospective study based on population-based breast cancer screening programme in China. *BMC Public Health* **25**, 1752 (2025).
39. Zeng, H. et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. *Lancet Public Health* **6**, e877–e887 (2021).
40. Lin, Y. et al. Diagnostic routes and symptom-to-treatment delays in gastric cancer: Findings from a cross-sectional study in southeastern China. *Public Health* **248**, 105934 (2025).
41. European Parliament. Directorate General for Parliamentary Research Services. Europe's beating cancer plan: implementation findings. (2025).
42. Renzi, C., Odelli, S., Morani, F., Benitez Majano, S. & Signorelli, C. Delays in cancer diagnosis: challenges and opportunities in Europe. *Acta Bio-Medica Atenei Parm.* **94**, e2023161 (2023).
43. EUCanScreen. Italy's 2024 Colorectal Cancer Screening Results. (2025).
44. AIHW. Australian Institute of Health and Welfare Annual Report. (2024).
45. Booker, R. Building bridges between clinic and community: Supporting patients and caregivers living in rural and remote Canada. *Can. Oncol. Nurs. J.* **33**, 509–516 (2023).

46. Normanno, N. et al. Access and quality of biomarker testing for precision oncology in Europe. *Eur. J. Cancer* **176**, 70–77 (2022).
47. Horgan, D. et al. Precision Oncology: A Global Perspective on Implementation and Policy Development. *JCO Glob. Oncol.* **11**, e2400416 (2025).
48. González-Martín, A. & Ledermann, J. A. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer. *ESMO Open* **11**, 106032 (2026).
49. Sabbagh, S. et al. Biomarker Testing Disparities in Metastatic Colorectal Cancer. *JAMA Netw. Open* **7**, e2419142 (2024).
50. Feldman, J. & Benjamin, D. Disparities in Global Oncology Workforce Have Consequences for Cancer Care. (2025).
51. Beating cancer inequalities: Current trends and key policy directions: Beating Cancer Inequalities in the EU | OECD. https://www.oecd.org/en/publications/beating-cancer-inequalities-in-the-eu_14fdc89a-en/full-report/component-5.html.
52. Wang, X., Pešić, M. & Podolski-Renić, A. Combination therapies in cancer treatment: enhancing efficacy and reducing resistance. *Front. Pharmacol.* **16**, (2026).
53. Lu, Z. et al. The landscape of cancer research and cancer care in China. *Nat. Med.* **29**, 3022–3032 (2023).
54. Australia Cancer Plan. Australian Cancer Plan. <https://www.australiacancerplan.gov.au/actions/5.2.1> (2026).
55. CAPCA. Pan-Canadian Strategic Oncology Workforce Report. (2025).
56. Bradford, N. et al. Cancer Nurses' Voices and Recommendations to Address Workforce Challenges: A Qualitative Analysis. *Semin. Oncol. Nurs.* **40**, 151722 (2024).
57. Australian Institute of Health and Welfare. Rural and remote health. (2025).
58. Welfare, N. H. I. A. M. of H. and. NHIA's Innovative Digital Governance for Cancer Treatment: Comprehensive Optimization of Precision Care. *National Health Insurance Administration Ministry of Health and Welfare* <https://www.nhi.gov.tw/en/cp-19445-c852a-8-2.html> (2025).
59. de Haart, K. et al. Long-term follow-up after authorization of gene therapy: leveraging real-world data. *Drug Discov. Today* **30**, 104337 (2025).
60. OECD. *Access to Oncology Medicines in EU and OECD Countries*. vol. 170 https://www.oecd.org/en/publications/access-to-oncology-medicines-in-eu-and-oecd-countries_c263c014-en.html (2024).
61. Yazdinejad, A. & Kong, J. D. Breaking interprovincial data silos: how federated learning can unlock Canada's public health potential. *R. Soc. Open Sci.* **13**, 250959 (2026).
62. Murgia, Y. et al. The challenges of national health data ecosystems in feeding the European health data space: the Italian example. *Front. Med.* **8**, (2025).
63. Parliament of Australia. Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer. 2024 https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Cancerdiagnosis/Report/Chapter_1_-_Introduction.
64. Jian, J. et al. Real-world data and evidence: pioneering frontiers in precision oncology. *J. Zhejiang Univ. Sci. B* **27**, 44–57 (2026).
65. Murphy, L., Akehurst, R., Cunningham, D., de Pouvourville, G. & Sola-Morales, O. Real-world evidence to support health technology assessment and payer decision making: is it now or never? *Int. J. Technol. Assess. Health Care* **31**, (2025).
66. Ergin, Y., Kassenaar, S., Macnair, S. & Mallious-Najjar, K. HTA 211Are Surrogate Endpoints a Way Forward in Non-Small Cell Lung Cancer (NSCLC)? A Comparison of HTA Outcomes Across Germany, France and the UK. *Value Health* **25**, S338 (2022).
67. Boukouvalas, S. & Ferguson, S. Challenges associated with surrogate endpoints for healthcare decision-making in oncology. *Value Health* (2023).

68. Landgren, O. & Devlin, S. M. Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap. *Blood Cancer Discov.* 6, 13–22 (2025).
69. Cao, S., Kan, H., Lu, M. & Pan, J. Estimating comparative effectiveness using Single-Arm trials: A challenge in the field of agnosticism. *BMC Med. Res. Methodol.* 25, 233 (2025).
70. Patel, D. et al. Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials. *Value Health* 24, 1118–1125 (2021).
71. Dasgupta, A. et al. HTA16 A Systematic Literature Review of the Mitigation Strategies to Overcome the Risk for Confounding of Overall Survival in Trials With Crossover/Treatment Switching Evaluated in Health Technology Assessments of Treatments for Select Tumors in Oncology. *Value Health* 28, S403.
72. Yan, Y. et al. Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States. *The Oncologist* 30, oyaf181 (2025).
73. Humanity. What Counts in Cancer Care - Humanity. (2025).
74. Ledermann, J. A. et al. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. *Ann. Oncol.* 35, 248–266 (2024).
75. Lemieux, C., Phua, C. W., Robinson, K. S., Owen, C. & Banerji, V. Contemporary Fixed-Duration Treatment Options in the First-Line Setting of Chronic Lymphocytic Leukemia: Perspectives from a Publicly Funded Healthcare System. *Curr. Oncol.* 32, 543 (2025).
76. AbbVie. The Emotional Impact of CLL on Diverse Patient Populations. (2025).
77. Pan, J. et al. List prices and clinical value of anticancer drugs in China, Japan, and South Korea: a retrospective comparative study. *Lancet Reg. Health West. Pac.* 47, 101088 (2024).
78. Ball, G., Levine, M. A. H., Thabane, L. & Tarride, J.-E. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia. *Curr. Oncol.* 29, 7624–7636 (2022).
79. Rawson, N. S. & Stewart, D. J. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada. *Clin. Outcomes Res.* 16, 437–445 (2024).
80. Hofmarcher, T., Charalambous, A., Normanno, N., Szmytke, E. & Wilking, N. Access to novel cancer medicines in Europe: inequities across countries and their drivers. *ESMO Open* 10, (2025).
81. Bayle, A. et al. ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe☆. *Ann. Oncol.* 34, 934–945 (2023).
82. OHE. Achieving Accelerated Patient Access to Cancer Care in Europe. (2025).
83. Newton, M., Stoddart, K., Travaglio, M. & Heron, E. EFPIA Patients W.A.I.T. Indicator 2025 Survey. 2026.
84. Godman, B. et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. *Expert Rev. Pharmacoecon. Outcomes Res.* 21, 527–540 (2021).
85. Henderson, N. et al. Balancing Budgets and Breakthroughs: Challenges and Solutions for Budget Impact Analysis of Gene Therapies. (2025).
86. Welfare, N. H. I. A. M. of H. and. A Leap in Cancer Treatment that Aligns with International Guidelines. National Health Insurance Administration Ministry of Health and Welfare <https://www.nhi.gov.tw/en/cp-18592-95e85-8-2.html> (2025).
87. IQVIA Institute. Achieving CAR T-cell Therapy Health System Readiness: An Assessment of Barriers and Opportunities. (2025).
88. Thavorn, K. et al. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review. *Value Health* 27, 1149–1173 (2024).
89. Michelsen, S., Nachi, S., Van Dyck, W., Simoens, S. & Huys, I. Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies. *Front. Pharmacol.* 11, 594446 (2020).

90. EFPIA. Access to oncology combination therapies in Europe: Moving Forward. (2024).
91. Ji-Yoon, H. Combination therapy faces reimbursement challenges for cancer patients in South Korea. <https://biz.chosun.com/en/en-science/2025/03/17/4HK34TSG4BDVPCMOMRP36ZII7M/> (2025).
92. EFPIA. Do Novel Oncology Combination Therapies Have a Place Within the EU Legislative Framework? The Impact of Challenges for Novel Combination Therapies on Equality of Access Between European Patients. (2023).
93. Gaultney, J. G. et al. Value attribution for oncology combination regimens: going beyond frameworks to balance innovation, access, and affordability. *Front. Pharmacol.* **16**, 1590944 (2025).
94. Izmirlijeva, M., Reinaud, F., Taiyeb, M. & Ando, G. Reimbursement Outcomes for Combination Therapies vs Monotherapies in Lung Cancer and Multiple Myeloma in the Top Five European Markets. *Value Health* **25**, S7 (2022).
95. OECD. *Addressing Challenges in Access to Oncology Medicines: Analytical Report*. https://www.oecd.org/en/publications/addressing-challenges-in-access-to-oncology-medicines_699520d0-en.html (2020) doi:10.1787/699520d0-en.
96. Rogoza, R. M., Husereau, D., Barot, P. & Millson, B. Challenges in Evaluating and Paying for Combination Therapies in Oncology - a Canadian Perspective. *ISPOR* (2022).
97. Yu, S. ADC-immunotherapy combo 'Padcev' + 'Keytruda' seen as strong candidate for reimbursement... 'clinical value clear'. *The Bio News* (2026).
98. Kim, W., Lee, S. C., Lee, W.-R. & Chun, S. The effect of the introduction of the national lung cancer screening program on short-term mortality in Korea. *Lung Cancer* **186**, 107412 (2023).
99. 2025. BreastScreen Australia monitoring report 2025. (2025).
100. British Columbia Gov News. Life-saving cancer therapy now being provided in British Columbia. (2024).
101. Chen, W., Zhang, S., Zou, N. & Zhao, P. Cancer incidence and mortality in China. (2011).
102. Zeng, H. et al. Cancer survival statistics in China 2019–2021: a multicenter, population-based study. *J. Natl. Cancer Cent.* **4**, 203–213 (2024).
103. Health Canada. Health Canada's position on the CADTH Guidance for Reporting RWE to Support Decision-making. (2023).
104. Kamae, I., Thwaites, R., Hamada, A. & Fernandez, J. L. Health technology assessment in Japan: a work in progress. *J. Med. Econ.* **23**, 317–322 (2020).
105. Yun-Mi, K. Korea eases path to breakthrough drugs with flexible ICER rules. *Korea Biomedical Review* (2025).
106. Dolon. Innovative Contracting for ATMPs in Europe. (2023).
107. Jorgensen, J. & Kefalas, P. The Use of Innovative Payment Mechanisms for Gene Therapies in Europe and the USA. *Regen. Med.* **16**, 405–422 (2021).